Recombinant Human PDGFRL Fc Chimera Protein, CF

Recombinant Human PDGFRL Fc Chimera (Catalog # 1723-PR) inhibits HCT-116 human Colorectal carcinoma proliferation. The ED50 for this effect is 1.5-9 μg/mL.

2 μg/lane of Recombinant Human PDGFRL Fc Chimera was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 69- 84 kDa and 140- 170 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human PDGFRL Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit proliferation of HCT-116 human colorectal carcinoma cells. The ED₅₀ for this effect is 1.5-9 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human PDGFRL protein
  

  Human PDGFRL (Gln22-Ser375) Accession # Q15198	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q15198
• N-terminal Sequence:
  Gln22 inferred from enzymatic pyroglutamate treatment revealing His23.
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 68 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 69-84 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human PDGFRL Fc Chimera Protein, CF

• PDGFRL
• PDGFR-Like Protein
• PDGRL
• platelet-derived growth factor receptor-like protein
• platelet-derived growth factor receptor-like
• platelet-derived growth factor-beta-like tumor suppressor
• PRLTS
• PRLTSPDGF receptor beta-like tumor suppressor

Background

Platelet-derived growth factor receptor-like protein is a 67 kDa glycoprotein protein consisting of two Ig-like C2-type domains. By sequence similarity, human PDGFRL is 90% similar to the mouse version and 91% similar to that of the rat. It is a secreted protein related to the class III subfamily of receptor tyrosine kinases (RTK), the platelet-derived growth factor receptors (1-5). PDGFRL is a tumor suppressor active in the tumor-suppression network and implicated in colorectal cancer, and a decrease in PDGFRL expression levels has been observed in breast cancer (1). A variant of PDGFRL is found to play a role in the development of Behçet disease, a complex immunoregulatory disease (6). The autoimmune role of PDGFRL is also supported by its up-regulation in a mouse model for Rheumatoid Arthritis (7). Study also showed that PDGFRL may play a role in chondrocyte proliferation and differentiation.

1. Guo, F-J. et al. (2010) World J Gastroenterol. 16:1465.
2. Andrae, J. et al. (2008) Genes Dev. 22:1276.
3. Heldin, C-H. and B. Westermark (1999) Physiol. Rev. 79:1283.
4. Claesson-Welsh, L. et al. (1989) Proc. Natl. Acad. Sci. USA 86:4917.
5. Matsui, T. et al. (1989) Science 243:800.
6. Hou, S. et al. (2013). Human Mutat. 34:74.
7. Fujikado, N. et al. (2006). Arthritis Res. & Ther. 8:R100.
8. Kawata, K. et al. (2017) J Cell Biochemistry. 118:4033.

Bioinformatics

• Uniprot:
  • Q15198()